Hemerion opens a new investigation site at Lille University Hospital dedicated to phase 1/2 clinical validation of its Pentalafen®/Heliance® therapy for the treatment of glioblastoma.
Hemerion opens a new investigation site at Lille University Hospital dedicated to phase 1/2 clinical validation of its Pentalafen®/Heliance® therapy for the treatment of glioblastoma.